Skip to main content
. 2021 Jul 31;23:204. doi: 10.1186/s13075-021-02573-0

Table 1.

Baseline characteristics

Parameter Mean (SD) Median Range
 Age (years) 48 (12) 47 28–67
 Weight (kg) 65 (9) 66 50–79
 Height (cm) 169 (8) 170 157–184
 Sex
  Female (n) 7
  Male (n) 2
 Disease duration (months) since
  Onset of Raynaud’s phenomenon 32 (38) 17 2–120
  Onset of skin involvement 20 (16) 16 8–58
 mRSS 28 (10) 25 19–46
 QoLa
  HAQ-DI 1.1 (0.6) 1.0 0.5–2.2
  SF-36 Physical component sum 35 (12) 37 17–48
Parameter Yes No Unknown
 Antinuclear antibody (ANA) positive (n) 9 0 0
 Anti-RNA polymerase III positive (n) 3 5 1
 Anti-topoisomerase I positive (n) 5 3 1
 Lung fibrosis (by high-resolution CT) (n) 3 6 0
 Pitting scars (n) 4 5 0
 Digital ulcers (n) 1 8 0
 Ongoing corticosteroid treatmentb (n) 3 6 0
 Previous immunosuppressive treatment (n) 0 9 0

SD standard deviation

aQoL-HAQ-DI is a disability index ranging from 0 to 3 where 0 means that certain activities can be done without difficulty and 3 means that these activities cannot be done at all. SF-36 is a health index where 0 means maximum disability and 100 means no disability. The SF-36 Physical component sum is a calculated score based on different questions related to physical health

bIndication was joint involvement in all 3 patients and doses equivalent to < 10 mg prednisolone per day